Expertise in
22
conditions

Dr. Rahul G. Argula

University Medical Associates Of The Medical University Of South Carol
Charleston, SC
Expertise in
22
conditions
Specialties:Intensive Care Medicine | Pulmonary Medicine
Accepting New Patients
Offers Telehealth
Expertise in
22
conditions
OverviewInsuranceLocationsClinical Research

Overview

Rahul Argula is an Intensive Care Medicine specialist and a Pulmonary Medicine provider in Charleston, South Carolina. Dr. Argula is highly rated in 22 conditions, according to our data. His top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Emphysema, and Sarcoidosis. Dr. Argula is currently accepting new patients.

His clinical research consists of co-authoring 25 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Intensive Care Medicine
Pulmonary Medicine
Licenses
Internal Medicine in SC
Hospital Affiliations
Musc Health Columbia Medical Center Downtown
Musc Medical Center
Musc Health Florence Medical Center
Languages Spoken
English
Hindi
Tamil
Telugu
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Blue Cross Blue Shield
  •  Humana

Locations

UNIVERSITY MEDICAL ASSOCIATES OF THE MEDICAL UNIVERSITY OF SOUTH CAROL
2810 Ashley Phosphate Rd, Suite B 11, Charleston, SC 29425
843-792-1414

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1 Proteinase Inhibitor (Human) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency
A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1 Proteinase Inhibitor (Human) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2025
Intervention Type: Biological, Other
Study Drug: Prolastin C
Study Phase: Phase 3
An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects With Pulmonary Arterial Hypertension Currently Using Tyvaso
An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects With Pulmonary Arterial Hypertension Currently Using Tyvaso
Enrollment Status: Completed
Publish Date: November 01, 2024
Intervention Type: Drug
Study Drug: Treprostinil Inhalation Powder
Study Phase: Phase 1
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: February 06, 2024
Intervention Type: Drug
Study Phase: Phase 3
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: February 06, 2024
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Enrollment Status: Terminated
Publish Date: November 24, 2023
Intervention Type: Drug
Study Drug: Inhaled treprostinil solution
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD
Enrollment Status: Terminated
Publish Date: July 27, 2023
Intervention Type: Combination product
Study Drug: INOpulse
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Other, Biological, Drug, Diagnostic test
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

25 Total Publications

Pathologic differences between systemic sclerosis-associated and idiopathic pulmonary arterial hypertension.
Pathologic differences between systemic sclerosis-associated and idiopathic pulmonary arterial hypertension.
Journal: Journal of scleroderma and related disorders
Published: August 20, 2024
Similar Doctors
Nichole T. Tanner
Expertise in
11
conditions
Dr. Nichole T. Tanner
Pulmonary Medicine | Intensive Care Medicine
Expertise in
11
conditions
Dr. Nichole T. Tanner
Pulmonary Medicine | Intensive Care Medicine

University Medical Associates Of The Medical University Of South Carol

171 Ashley Ave, 
Charleston, SC 
 (12.0 mi)
843-792-1414
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nichole Tanner is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Charleston, South Carolina. Dr. Tanner is highly rated in 11 conditions, according to our data. Her top areas of expertise are Lung Nodules, Lung Cancer, Lung Adenocarcinoma, ALK-Positive Non-Small Cell Lung Cancer, and Endoscopy. Dr. Tanner is currently accepting new patients.

Expertise in
12
conditions
Dr. Christopher R. Gilbert
Intensive Care Medicine | Cardiology | Pulmonary Medicine
Expertise in
12
conditions
Dr. Christopher R. Gilbert
Intensive Care Medicine | Cardiology | Pulmonary Medicine

University Medical Associates Of The Medical University Of South Carol

171 Ashley Ave, 
Charleston, SC 
 (12.0 mi)
843-792-1414
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Christopher Gilbert is an Intensive Care Medicine specialist and a Cardiologist in Charleston, South Carolina. Dr. Gilbert is highly rated in 12 conditions, according to our data. His top areas of expertise are Pleural Effusion, Empyema, Lung Nodules, Endoscopy, and Gastrostomy. Dr. Gilbert is currently accepting new patients.

Expertise in
16
conditions
Dr. Charlton B. Strange
Intensive Care Medicine | Pulmonary Medicine
Expertise in
16
conditions
Dr. Charlton B. Strange
Intensive Care Medicine | Pulmonary Medicine

University Medical Associates Of The Medical University Of South Carol

167 Ashley Ave, 
Charleston, SC 
 (12.1 mi)
843-792-1414
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Charlton Strange is an Intensive Care Medicine specialist and a Pulmonary Medicine provider in Charleston, South Carolina. Dr. Strange is highly rated in 16 conditions, according to our data. His top areas of expertise are Alpha-1 Antitrypsin Deficiency (AATD), Emphysema, Lung Metastases, and Pneumonia. Dr. Strange is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile